Concord Medical Services Holdings (FRA:C2C) Return-on-Tangible-Equity: 0.00% (As of Dec. 2025)


FRA:C2C Concord Medical Services Holdings Ltd FRA:C2C
51 GF Score
Price €6.25
GF Value €9.81
! 6 Warning Signs
View Full Analysis

What is Concord Medical Services Holdings Return-on-Tangible-Equity?

Concord Medical Services Holdings FRA:C2C 51 Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus rates FRA:C2C with a GF Score™ of 51/100 and a GF Value™ of €9.81. The stock has 6 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Concord Medical Services Holdings ranks worse than 172711.4% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Concord Medical Services Holdings's annualized net income for the quarter that ended in Dec. 2025 was €-15.93 Mil. Concord Medical Services Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €-386.95 Mil. Therefore, Concord Medical Services Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.

The historical rank and industry rank for Concord Medical Services Holdings's Return-on-Tangible-Equity or its related term are showing as below:

FRA:C2C's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.13
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Concord Medical Services Holdings  (FRA:C2C) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Concord Medical Services Holdings Return-on-Tangible-Equity Related Terms


Concord Medical Services Holdings Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Concord Medical Services Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Medical Services Holdings Return-on-Tangible-Equity Chart

Concord Medical Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Concord Medical Services Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:C2C vs CCEL, GBCS, CDIX: Return-on-Tangible-Equity Comparison

For the Medical Care Facilities subindustry, Concord Medical Services Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Medical Services Holdings Return-on-Tangible-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Concord Medical Services Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Concord Medical Services Holdings's Return-on-Tangible-Equity falls into.


FRA:C2C
51GF Score
Concord Medical Services Holdings Ltd FRA:C2C
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Medical Services Holdings Return-on-Tangible-Equity Calculation

Concord Medical Services Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-11.253/( (-463.417+-401.324 )/ 2 )
=-11.253/-432.3705
=N/A %

Concord Medical Services Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-15.926/( (-372.575+-401.324)/ 2 )
=-15.926/-386.9495
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Concord Medical Services Holdings (FRA:C2C) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Concord Medical Services Holdings and its competitors. According to the industry distribution chart, Concord Medical Services Holdings ranks #999999 out of 579 companies in the Healthcare Providers & Services industry.
Is Concord Medical Services Holdings' Return-on-Tangible-Equity too high?
Concord Medical Services Holdings' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Concord Medical Services Holdings ranks #999999 out of 579 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Concord Medical Services Holdings has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' Return-on-Tangible-Equity compare to CCEL and GBCS?
According to the Healthcare Providers & Services industry distribution chart, Concord Medical Services Holdings ranks #999999 out of 579 companies for Return-on-Tangible-Equity. This places Concord Medical Services Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Concord Medical Services Holdings and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Medical Services Holdings's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current Return-on-Tangible-Equity of 0.00%. The stock's GF Value™ is €9.81, compared to a current price of €6.25 — trading 36.3% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Concord Medical Services Holdings' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued. The current stock price of €6.25 is trading 36.3% below its estimated GF Value™ of €9.81.

Key valuation signals for FRA:C2C:

  • Return-on-Tangible-Equity: 0.00%
  • GF Value™: €9.81 vs. price of €6.25 (36.3% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Medical Services Holdings Business Description

Other Exchanges CCM:USA
Address Hanwei Plaza Building, No. 7 Guanghua Road, Room A1-A5, 26th Floor, East Area, Chaoyang District, Beijing, CHN, 100020
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
51GF Score

Get the complete analysis for FRA:C2C

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.25
Price
€9.81
GF Value